ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Family Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

7,348Medicare Part D Prescriptions Filled, Including Refills

Rank: 70 out of 1300

$645K Total Retail Price of All Prescriptions

Rank: 18 out of 1300

405 Patients Receiving at Least One Drug in Part D
91%Patients 65 Years and Older
9% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Colorado
Lower avg

Schedule Two
Controlled Substances

7% of this provider’s 405 patients filled at least one prescription for a schedule two drug, compared to an average of 8%.

Schedule Three
Controlled Substances

9% of this provider’s 405 patients filled at least one prescription for a schedule three drug, compared to an average of 9%.

Risky Drugs to Seniors

2% of this provider’s 6,670 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

31% of this provider’s prescriptions were for brand-name drugs, compared to an average of 23%.

Prescription Price

$88 was the average price of a prescription from this provider, compared to $53 among peers.

Prescriptions per Patient

18 is the average number of prescriptions (including refills) per patient, compared to an average of 15.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Colorado
SIMVASTATIN 249 229 1 3
LEVOTHYROXINE SODIUM 247 247 2 1
OMEPRAZOLE 206 190 3 4
DIOVAN 193 189 4 66
LISINOPRIL 176 172 5 2
WARFARIN SODIUM 175 160 6 9
ATORVASTATIN CALCIUM 173 161 7 13
AMLODIPINE BESYLATE 158 139 8 6
LEVOXYL 153 143 9 161
ZOLPIDEM TARTRATE 148 137 10 14
BENAZEPRIL HCL 140 133 11 94
LOSARTAN POTASSIUM 134 120 12 16
HYDROCODONE-ACETAMINOPHEN 133 115 S3 13 5
METFORMIN HCL 132 123 14 7
METOPROLOL TARTRATE 132 127 14 11
CARVEDILOL 127 123 16 38
TAMSULOSIN HCL 119 97 17 25
TORSEMIDE 115 89 18 171
PRAVASTATIN SODIUM 97 95 19 23
METOPROLOL SUCCINATE 85 85 20 24
PANTOPRAZOLE SODIUM 85 67 20 36
POTASSIUM CHLORIDE 84 84 22 18
CYMBALTA 84 78 22 44
FLUTICASONE PROPIONATE 80 72 24 30
ALLOPURINOL 79 75 25 29
FUROSEMIDE 76 76 26 8
DONEPEZIL HCL 71 67 27 32
NAMENDA 70 70 28 51
GABAPENTIN 65 58 29 15
ATENOLOL 62 62 30 12
CRESTOR 62 49 30 39
CELEBREX 54 54 32 95
VENLAFAXINE HCL ER 53 49 33 69
EXELON 52 52 34 251
LOVASTATIN 51 51 35 22
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Aug. 8, 2013.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.